CD47 and cancer: In order to kill cancer cells and sabotage CD47-SIRPa (CD47-signal regulatory protein alpha) connections, the hybrid cell membrane nanovesicles, or hNVs, can interface with circulating tumour cells (CTCs) in vascular lumens and accumulate at the site of resection (48).